Immunotherapy | Topics

Retrospective data suggest survival outcomes were positive and safety was reasonable for patients with cancer aged 80 years or older who received immune checkpoint inhibitors.

Patients with advanced cancers who were ineligible for trials were more likely to receive frontline immune checkpoint inhibitor monotherapy than patients with the same advanced cancers who were eligible for trials.

Roy S. Herbst, MD, PhD, shares insight on approaching clinical decision-making for the length of immunotherapy treatment and drug holidays for patients with NSCLC.

An expert in thoracic oncology provides an overview of ctDNA and discusses what ctDNA testing results can indicate about a patient’s likelihood of responding to immunotherapy in NSCLC.

Roy S. Herbst, MD, PhD, reviews indicators of relapse or progression of disease when monitoring patients on therapy in NSCLC.

Roy S. Herbst, MD, PhD, provides insight on selecting the optimal therapy for non–small-cell lung cancer and shares considerations for the use of combination chemotherapy and immunotherapy.

CancerNetwork® sat down with Jason Luke, MD, at the 2021 European Society for Medical Oncology Congress to talk about the latest developments in the use of immunotherapy for metastatic disease.

The toxicity profiles of PD-1 and PD-L1 inhibitors displayed unique characteristics when combines with other agents such as chemotherapy, targeted therapy, and immunotherapy.

A new treatment arm of a phase 2 trial examining PDS0101 plus pembrolizumab in patients with HPV-related head and neck cancers will be opened to patients with immune checkpoint inhibitor–pretreated disease.

Marron discussed the primary objectives and early data from a phase 1 trial presented at the virtual AACR Annual Meeting regarding the neoantigen peptide vaccine, PGV-001.